Evidence map›Paper›PMID 34888713›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Current Approaches of Building Mechanistic Pharmacodynamic Drug-Target Binding Models.

Jingyi Liang, Vi Ngoc-Nha Tran, Colin Hemez, Pia Abel Zur Wiesch

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jingyi Liang *Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway.
Vi Ngoc-Nha Tran *Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway.
Colin HemezGraduate Program in Biophysics, Harvard University, Boston, MA, USA.
Pia Abel Zur WieschDepartment of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway. pzw@daad-alumni.de.

Funding

MOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6M
NIGMS NIH HHS T32 GM008313
6 · The paper itself

Abstract

Mechanistic pharmacodynamic models that incorporate the binding kinetics of drug-target interactions have several advantages in understanding target engagement and the efficacy of a drug dose. However, guidelines on how to build and interpret mechanistic pharmacodynamic drug-target binding models considering both biological and computational factors are still missing in the literature. In this chapter, current approaches of building mechanistic PD models and their advantages are discussed. We also present a methodology on how to select a suitable model considering both biological and computational perspectives, as well as summarize the challenges of current mechanistic PD models.

Indexed as

Models, BiologicalDose-Response Relationship, DrugDrug Delivery SystemsDrug DesignDrug InteractionsPhagocytosisPharmaceutical PreparationsPharmaceutical PreparationsDifferential equationsDrug–target binding kineticsMathematical biologyMechanistic modelsModel selectionOccupancy–efficacy relationshipParameter estimationPharmacodynamicsPK-PD simulation tools

Identifiers

PMID34888713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.